PROCARBAZINE, VINCRISTINE, CCNU, AND CYCLOPHOSPHAMIDE (POCC) IN THE TREATMENT OF METASTATIC MALIGNANT-MELANOMA

1 January 1980

journal article
research article

Vol. 64 (1) , 139-142

Abstract

Previously untreated patients (12) with histologically documented, metastatic malignant melanoma were treated with the combination of procarbazine, vincristine, CCNU and cyclophosphamide, with an objective response rate of 33%. The median survival time was 10 mo. for responders vs. 5 mo. for nonresponders. Bone marrow suppression was the major toxic effect. Further clinical trials are needed to better assess the utility of this combination in advanced melanoma.

This publication has 3 references indexed in Scilit:

Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma
Cancer, 1977
Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine
Cancer, 1976
Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma
Cancer, 1976